Crescita Therapeutics Inc. CTX.TO
Jun 4, 2026, 9:30 AM EDT
- YTD
- +64.58%
- 1 year
- +49.06%
- Market cap
- 11.28M
- Revenue (ttm)
- 17.40M
- Profit margin
- -15.73%
- EPS (ttm)
- -0.14
- Shares out
- 19.12M
- P/E ratio
- -42.52
- YTD return
- +64.58%
- 1-year return
- +49.06%
- Volume
- 1.00K
- Avg volume
- 18.76K
- Open
- 0.79
- Previous close
- 0.79
- Day's range
- 0.79 – 0.79
- 52-week range
- 0.36 – 0.69
- Beta
- 1.71
Key statistics
- Enterprise value
- 3.00M
- PEG ratio
- 0.00
- Price / sales
- 0.65
- Price / book
- 0.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 18.50%
- Free cash flow
- -558.25K
- Total cash
- 8.44M
- Total debt
- 926.00K
- Return on equity
- -15.57%
- Short % of float
- 0.00%
- 50-day average
- 0.5788
- 200-day average
- 0.52775
Next earnings
Consensus EPS estimate 0.00.
About Crescita Therapeutics Inc.
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations that can deliver actives into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; a development and commercialization license agreement with Taro Pharmaceuticals Inc.; and a distribution and promotion agreement with FILLMED. Crescita Therapeutics Inc. was founded in 2016 and is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- crescitatherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CTX.TO — it syncs with the Stock Master app.